<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="cd47-inflammation-dlbcl-siregar-pb3312">
    <meta name="study:title" content="PB3312 - Association of CD47 expression and systemic inflammation in diffuse large B-cell lymphoma patients">
    <meta name="study:fileName" content="Abstracts/CD47-INFLAMMATION-DLBCL-SIREGAR-PB3312.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="Not Specified">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="">

    <title>PB3312: CD47 Expression & Inflammation in DLBCL (Siregar)</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3312 - CD47 Expression & Systemic Inflammation in DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim</h4>
                    <p>DLBCL patients (N=107). Aim: Investigate the role of CD47 expression in systemic inflammation (NLR).</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M4.5 2.25A2.25 2.25 0 002.25 4.5v15A2.25 2.25 0 004.5 21.75h15A2.25 2.25 0 0021.75 19.5V4.5A2.25 2.25 0 0019.5 2.25h-15zm9.75 10.178a.75.75 0 00-1.5 0v2.872l-1.6-1.6a.75.75 0 10-1.06 1.061l2.353 2.353a.75.75 0 001.061 0l2.353-2.353a.75.75 0 00-1.06-1.06l-1.591 1.591v-2.873zm-6.75-4.428a.75.75 0 01.75-.75h4.5a.75.75 0 010 1.5h-4.5a.75.75 0 01-.75-.75z" clip-rule="evenodd" />
                    </svg>
                    <h4>Methodology</h4>
                    <p>Retrospective cohort. CD47 by IHC (low/high). NLR from records (low/high by ROC cut-off 3.43). Response by RECIL.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M17.25 9.11v5.38a4.502 4.502 0 01-4.5 4.5h-3a4.502 4.502 0 01-4.5-4.5V9.11A4.502 4.502 0 019.75 4.61h.046a4.5 4.5 0 014.408 4.065 2.25 2.25 0 004.419.426.75.75 0 00-1.34-.504 2.25 2.25 0 00-4.075-1.316 3.001 3.001 0 00-2.965-2.632H9.75A4.502 4.502 0 0114.25 0h.09a4.502 4.502 0 014.41 4.41v4.7zM5.25 12A2.25 2.25 0 003 14.25v3A2.25 2.25 0 005.25 19.5h3A2.25 2.25 0 0010.5 17.25v-3A2.25 2.25 0 008.25 12h-3z" />
                    </svg>
                    <h4>Key Findings</h4>
                    <p>CD47<sup>high</sup> assoc. w/ high NLR (70.2% vs 50.8%, p=0.044). CD47<sup>high</sup> & high NLR assoc. w/ lower CR rates (CD47: 33.3% vs 62.1%, p=0.003; NLR: 41.3% vs 61.9%, p=0.038).</p>
                </div>
                <div class="visual-abstract-item">
                   <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zM12.75 6a.75.75 0 00-1.5 0v6c0 .414.336.75.75.75h4.5a.75.75 0 000-1.5h-3.75V6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>CD47 expression is upregulated in DLBCL, associated with treatment response. Stronger CD47 expression contributes to augmented inflammation. Targeting CD47 promising.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3312: Association of CD47 expression and systemic inflammation in diffuse large B-cell lymphoma patients</h1>
            <p class="abstract-sub-header">Nia Siregar, Cosphiadi Irawan, Maria Ham, Ikhwan Rinaldi</p>
            <p class="abstract-meta-info mt-2">EHA Library PB3312 | Abstract Release: 05/14/2025 | Publication Only: 06/12/2025</p>
        </div>

        <div class="grid md:grid-cols-12 gap-x-8 gap-y-6">
            <div class="md:col-span-8">
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-2 pl-2">
                        <li>CD47, a macrophage immune checkpoint, is part of the complex tumor microenvironment (TME) in lymphoma.</li>
                        <li>The TME is modified by inflammatory cells; systemic inflammatory response and host immunity are important in tumor progression.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm">This study aimed to reveal the role of CD47 expression in systemic inflammation of diffuse large B-cell lymphoma (DLBCL) patients.</p>
                </div>
                
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li><strong>Study Type:</strong> Retrospective cohort study.</li>
                        <li><strong>Patient Population:</strong> DLBCL patients from 4 hospitals (Jan 2017 - Aug 2021).</li>
                        <li><strong>Systemic Inflammation Marker:</strong> Neutrophil-Lymphocyte Ratio (NLR) obtained from medical records. NLR grouped by ROC curve cut-off.</li>
                        <li><strong>CD47 Expression:</strong> Immunohistochemical (IHC) staining on formalin-fixed paraffin-embedded (FFPE) tumor tissues.
                            <ul class="list-circle list-inside ml-4 mt-1">
                                <li>Assessed on membrane and/or cytoplasm of tumor cells.</li>
                                <li>Grouped: CD47<sup>low</sup> (score 0-2) and CD47<sup>high</sup> (score 3-4).</li>
                            </ul>
                        </li>
                        <li><strong>Treatment Response:</strong> Assessed using RECIL criteria.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Study Overview</h3>
                        <div class="schema-step">
                            <strong>Patient Cohort (N=107)</strong>
                            <span>DLBCL Patients (2017-2021)</span>
                            <span>Data from 4 Hospitals</span>
                        </div>
                        <div class="schema-arrow-down">â–¼</div>
                        <div class="schema-step">
                            <strong>Data Collection & Analysis</strong>
                            <span>NLR from medical records (ROC cut-off)</span>
                            <span>CD47 expression by IHC from FFPE (Low vs High)</span>
                            <span>Treatment response by RECIL criteria</span>
                        </div>
                        <div class="schema-arrow-down">â–¼</div>
                        <div class="schema-assessment-points">
                           <span>Association between CD47 group and NLR group</span>
                           <span>Association of CD47 intensity & NLR with treatment response (CR)</span>
                        </div>
                    </div>
                </div>
            </div>

            <div class="md:col-span-4">
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=107)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Total subjects analyzed: 107.</li>
                        <li>Median percentage of cells positively expressing CD47: 86.5%.</li>
                        <li>NLR cut-off from ROC: 3.43.</li>
                    </ul>
                    <div class="table-container compact-table mt-3">
                        <table>
                            <thead>
                                <tr><th>Parameter</th><th>Value/Finding</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Total Subjects</td><td>107</td></tr>
                                <tr><td>Median CD47+ Cells</td><td>86.5%</td></tr>
                                <tr><td>NLR ROC Cut-off</td><td>3.43</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Key Findings (N=107)</h2>
                    <h3 class="abstract-sub-section-title">CD47 Expression & NLR:</h3>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>CD47 group was significantly associated with NLR group (p=0.044).</li>
                        <li>Higher proportion of subjects with high NLR (>3.43) in CD47<sup>high</sup> group vs. CD47<sup>low</sup> group (70.2% vs. 50.8%).</li>
                    </ul>
                     <div class="infographic-item-group mb-3">
                        <div class="infographic-item teal-theme">
                            <div class="infographic-icon icon-teal">ðŸ”—</div>
                            <div class="infographic-value">CD47<sup>high</sup> â‡” High NLR</div>
                            <div class="infographic-label">Significant Association (p=0.044)</div>
                        </div>
                    </div>

                    <h3 class="abstract-sub-section-title">CD47, NLR & Treatment Response (Complete Remission - CR):</h3>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Intensity of CD47 expression significantly associated with treatment response.
                            <ul class="list-circle list-inside ml-4 mt-1">
                               <li>CD47<sup>high</sup>: Lower CR rate vs. CD47<sup>low</sup> (33.3% vs. 62.1%, p=0.003).</li>
                            </ul>
                        </li>
                        <li>NLR significantly associated with treatment response.
                            <ul class="list-circle list-inside ml-4 mt-1">
                                <li>High NLR: Lower CR rate vs. low NLR (41.3% vs. 61.9%, p=0.038).</li>
                            </ul>
                        </li>
                    </ul>
                     <div class="grid grid-cols-1 gap-3 mt-3">
                        <div class="infographic-item orange-theme">
                            <div class="infographic-icon icon-orange">ðŸ“‰</div>
                            <div class="infographic-value">Lower CR</div>
                            <div class="infographic-label">CD47<sup>high</sup> (33.3% vs 62.1%, p=0.003)</div>
                        </div>
                        <div class="infographic-item orange-theme">
                            <div class="infographic-icon icon-orange">ðŸ“‰</div>
                            <div class="infographic-value">Lower CR</div>
                            <div class="infographic-label">High NLR (41.3% vs 61.9%, p=0.038)</div>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-2 pl-2">
                <li>CD47 expression is upregulated in DLBCL patients and is associated with treatment response.</li>
                <li>Stronger expression of CD47 (CD47<sup>high</sup>) contributes to augmented systemic inflammatory responses (higher NLR) in DLBCL.</li>
                <li>Both CD47<sup>high</sup> status and high NLR are associated with a lower proportion of patients achieving complete remission.</li>
                <li>These findings suggest that targeting CD47 might be a promising treatment strategy for DLBCL.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>
                CD, Cluster of Differentiation; CR, Complete Remission; DLBCL, Diffuse Large B-Cell Lymphoma; FFPE, Formalin-Fixed Paraffin-Embedded; IHC, Immunohistochemistry; NLR, Neutrophil-Lymphocyte Ratio; RECIL, Response Evaluation Criteria In Lymphoma; ROC, Receiver Operating Curve; TME, Tumor Microenvironment.
            </p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-4 h-4 mr-1.5">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Siregar N, Irawan C, Ham M, et al. Association of CD47 expression and systemic inflammation in diffuse large B-cell lymphoma patients. Abstract #PB3312 presented at European Haematology Association (EHA) June 12, 2025, City, Country.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA Library PB3312 | Publication Only: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script> 
</body>
</html>
